A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies

NCT03560882 | Active Not Recruiting Phase 1 DMC FDA Drug

• 1 other identifier: IIT-2018-p53Atorva
• Study Type: interventional
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

This is a window-of-opportunity trial to determine if atorvastatin given for 1 to 4 weeks at a dose of 80 milligrams per day (mg/day) is sufficient to decrease the level of conformational mutant tumor protein 53 (p53) in malignant diseases (solid tumor and relapsed Acute Myeloid Leukemia (AML)).

Conditions

Malignant Disease; Solid Tumor; Acute Myeloid Leukemia; Myelodysplastic Syndromes; Cancer; Relapsed Hematologic Malignancy

Keywords

atorvastatin; p53; tumor resection

Outcome Measures

Primary Outcomes (1)

• Change in conformational mutant tumor protein 53 (p53)

  Measured by immunohistochemistry (IHC) staining. Reported as overall percent difference in the level of conformation mutant p53.

  baseline and up to 4 weeks

Secondary Outcomes (2)

• Change in Ki-67 (protein)

  baseline and up to 4 weeks

• Change in caspase-3

  baseline and up to 4 weeks

Study Arms (1)

Atorvastatin

EXPERIMENTAL

Atorvastatin 80 milligrams (mg) per day, orally for 1 - 4 weeks before surgery (surgery not part of clinical trial)

Drug: Atorvastatin

Interventions

Atorvastatin DRUG

Atorvastatin tablet, 80mg

Atorvastatin

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Ability of participant to understand this study, and participant to sign a written informed consent. Legally authorized representative is not allowed to sign consent for participant.
• Participants with tumor protein 53 (TP53) immunohistochemistry (IHC)-positive tumors
• Participants whose screening IHC shows TP53-IHC-negative including wild type (WT) and null.
• Participants with histologic or cytologic confirmation of any malignant disease who are planning and eligible to undergo surgical resection. For participants with Solid Tumors Only
• Participants with previously treated acute myeloid leukemia (AML) are eligible if they relapse and are in between two treatment regimens
• No concurrent or recent (within 30 days) use of systemic therapy including chemotherapy, immunotherapy, hormonal therapy, cancer vaccine, or local therapy for the cancer.
• Formalin-fixed paraffin-embedded (FFPE) tumor tissue deemed adequate for IHC analysis and next generation sequencing (NGS) are required. Bone marrow aspirate tissue samples from participants with AML are required.
• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
• Adequate organ and marrow function
• A negative urine or serum pregnancy test within 7 days before Day 1 dose of study medication, if female participant is of childbearing potential.
• Women of child-bearing potential and men with partners of child-bearing potential must agree to practice sexual abstinence, or to use two forms of adequate contraception (hormonal AND barrier method of birth control) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. If a woman becomes pregnant or suspects she is pregnant while participating in this study, she should inform her treating physician immediately.

You may not qualify if:

• Current or anticipated use of other investigational agents while participating in this study.
• Pregnant or breast feeding.
• Diagnosis of squamous cell cancer of the oropharynx
• Previous malignancies (except non-melanoma skin cancers, and the following in situ cancers: bladder, gastric, colon, endometrial, cervical/dysplasia, melanoma, or breast), unless a complete remission was achieved at least 2 years prior to study entry AND no additional therapy is required during the study period
• Prior use of statins in the past 30 days.
• History of rhabdomyolysis
• Active liver disease
• Participants who currently consume substantial quantities of alcohol (Male, more than 4 drinks a day, Female, more than 2 drinks a day)
• Concurrent use of drugs associated with myopathy
• Hypersensitivity to atorvastatin or any component of the formulation
• Untreated hypothyroidism
• Inability to comply with study and follow-up procedures as judged by the Investigator

Sponsors & Collaborators

• Joaquina Baranda: lead

Study Sites (1)

University of Kansas Cancer Center - CRC

Fairway, Kansas, 66205, United States

Location

MeSH Terms

Conditions

Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Neoplasms; Hematologic Neoplasms

Interventions

Atorvastatin

Condition Hierarchy (Ancestors)

Leukemia, Myeloid; Leukemia; Neoplasms by Histologic Type; Hematologic Diseases; Hemic and Lymphatic Diseases; Bone Marrow Diseases; Neoplasms by Site

Intervention Hierarchy (Ancestors)

Pyrroles; Azoles; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Heptanoic Acids; Fatty Acids; Lipids

Study Officials

• Joaquina Baranda, MD

  The University of Kansas Cancer Center

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Associate Professor University of Kansas Cancer Center - Medical Oncology

Study Record Dates

• First Submitted: June 6, 2018
• First Posted: June 18, 2018
• Study Start: July 19, 2018
• Primary Completion: October 14, 2022
• Study Completion (Estimated): August 1, 2026
• Last Updated: May 6, 2026

Record last verified: 2026-04

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)